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Results. From the 95 patients treated, we analyse the subgroup of 85 patients who had enough follow-up to evaluate late toxicity.
The mean age at treatment was 67 (range 45–92). Most of the tumors were located at external superior cuadrant (41.2%) or joint
of superior cuadrants (15.3%). Eighty per cent were inﬁltrating ductal carcinomas with an 84.7% of stage IA tumors and 70% of
luminal A molecular subtypes. Only 6 patients were grade 3, they were treated with HDR-BT due to their age. Fifty-one patients
received adjuvant hormonal therapy. Most patients (70.6%) were treated using 7 needles (range 4–12) in 2–3 planes, with a mean
active length of 4.5 cm (range 2–7 cm). With a mean follow-up of 23.47 months (range 6–124), only one patient has experimented
a recurrence in the ipsilateral breast 21 months after the procedure, she had a triple negative tumor and was treated with
mastectomy without disease nowadays. Three patients died from another non-related disease (cerebral-vascular stroke), none
of them died from breast cancer disease. Late toxicity was mild, with 27% and 5% of grade I cutaneous and subcutaneous toxicity
respectively.
Conclusions. Accelerated partial breast irradiation using HDR-BT is a proper approach, with excellent results in terms of disease
free survival and very good tolerance in terms of normal tissue late toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.703
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Purpose. Low dose rate (LDR) prostate brachytherapy is an accepted, effective and safe therapy for localized prostate cancer in
patients with transurethral resection. We analyzed oncologic outcome, side-effects and complications after I-125 brachytherapy
based on 11 years of experience.
Methods and materials. Between June 2000 and December 2005, 56 consecutive patients were treated with clinically localized
prostate cancer. No patients received external beam radiation. All of them underwent LDR prostate brachytherapy. Biochemi-
cal failure was deﬁned according to the “Phoenix consensus”. Patients were stratiﬁed as intermediate risk based on D’Amico
deﬁnition.
Results. The median follow up time for these 56 patients was 100 months; 2 had a clinical relapse and 4 had biochemical relapse.
The 11-year actuarial biochemical control was 92%, (SD ±3%) for overall group. The multivariate Cox regression analyses no
identiﬁed, independent prognostic factors for biochemical failure. The actuarial biochemical control with Gleason score was 93%
and 88% for patients with Gleason score of ≤6 and =7, respectively. The biochemical control was 95%, and 85% for patients with
PSA of ≤10 and >20ng/ml, respectively. A patient reported incontinence after treatment (1,7%). Acute urinary retention was seen
in 2 (3.5%). Gastrointestinal toxicity grade III–IV has been observed in 2 patients (3.5%).
Conclusions. The excellent long-term results and low morbidity presented, as well as the many advantages of prostate brachyther-
apy over other treatments, demonstrates that brachytherapy is an effective treatment for patients with transurethral resection
and clinical organ-conﬁned prostate cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.704
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Purpose/objective. Study the blood supply of uveal melanoma as a sign of tumoral activity and quantify its presence after
brachytherapy.
Materials and methods. 50 cases treated with brachytherapy were reviewed from July 2005 to June 2010. Mean follow-up was 29
months (13.7–69 months). Duplex Doppler scans (gray scale and Doppler scans) were done at diagnosis and every 6 months after
treatment. Presence of intratumoral vessels, maximum systolic and diastolic velocity and resistance index were evaluated. The
average age was 60 years; 26 ♂ and 24 ♀. Mean basal size and thickness at diagnosis were 12.1mm×5.6mm (SD 3.0–5.6). The
most used plaque was COMS type. Apical dose was 85Gy.
Results. Doppler detected intratumoral vascularization at diagnosis in 21/50 cases, 7 persisted at 6, 12 and 18 months, to 24
months 5/31, 30 months 3/20, 36 months 1/12, 42 months 1/6, 48 months 1/3, 54 months 1/2 and 60 months 0/1. Mean systolic
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peak velocity (SPV) at diagnosis was 25.2±16.1 cm/s, and 15.82±10.5 at 6 months. Of those with persistent Doppler signal, 2
were big, 1 developed metastasis and 4 regressed. 8 avascular tumors at diagnosis experienced new vascularization: 1 recurred, 7
regressed and 4 of them developed neovascular glaucoma (NVG). Reduction in thickness was bigger when tumors vascularized,
lost Doppler signals. SPV decreased signiﬁcantly at 6 months (p=0.028), but not the diastolic peak (p=0.116).
Conclusion. Doppler scan is an important tool in the management of melanoma after plaque. Majority of tumors lost its Doppler
signal in the ﬁrst 6 months. Persistent intratumoral vessels are associated to big tumour size, recurrence or vascular congestion.
New vascularized cases can be explained by persistence of old vessels, recurrence or NVG. We recommend supporting these
ﬁndings with the current tests in direct ophthalmoscopy and ultrasound.
http://dx.doi.org/10.1016/j.rpor.2013.03.705
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Purpose. The aim of this study was to evaluate the efﬁcacy and toxicity of combining external beam radiation therapy (EBRT) and
high-dose-rate brachytherapy (HDRB) as a boost, in terms of biochemical relapse in patient (pts) with prostate cancer.
Methods and materials. From 2002 to July 2012, 377 pts with a diagnosis of intermediate-high risk prostate cancer were treated with
EBRT followed by supplemental HDRB. The characteristics were: mean age 65.78 (41–86 years), Gleason was 7 in 191 pts (50.7%)
and 8 or higher in 131 (35%), 226 pts. (60%) had a PSA>10ng/ml, T3 stage 263 pts (70%), T2 64 (17%) and T1 49 (13%). The EBRT
total mode dose was 60.0Gy (45–70Gy) on prostate and seminal vesicles. 120 pts (31%) also received a mode of 46Gy (45–50Gy)
on minor pelvis. All pts received a mode single-fraction of 9Gy (9–15) of HDRB-boost. Complete androgen deprivation was given
to 353 pts (93.63%).
Results. The mean follow-up was 48.72 months (6–126). The 5 and 7-year actuarial overall survival was 88% (CI 95%: 84–92) and
75% (CI 95%: 68–83). Cause speciﬁc survival at 5 and 7 years was 98% (CI 95%: 97–99) and 97% (CI 95%: 96–98) respectively. Disease
free survival was 93% (CI 95%: 89–97) and 91% (CI 95%: 87–95). The 5 and 7-year biochemical free relapse was 91% (CI 95%: 87–95)
and 89% (CI 95%: 83–95). The gastrointestinal grade 2–3 late-toxicity was observed in 17 pts (4.6%) and 6 pts (0.8%) respectively.
Genitourinary grade 2–3 toxicity was observed in 46 pts (12.2%) and 3 pts (1.6%).
Conclusion. The ﬁndings after long-term follow-up of intermediate-high risk prostate cancer pts treated with EBRT plus supple-
mental HDRB boost conﬁrmed the effectiveness of this fractionation schedule in terms of discomfort, treatment-related toxicity
and biochemical control.
http://dx.doi.org/10.1016/j.rpor.2013.03.706
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Objective. To evaluate the feasibility and toxicity of high-dose-rate (HDR)-brachytherapy (BT) as monotherapy in a prospective
clinical trial consisting of a single implant and two fractions (13.5Gy×2) for a total dose of 27Gy, delivered within 1 day for
localized prostate cancer. We report the acute and early chronic genitourinary (GU) and gastrointestinal toxicity (GI).
Methods and materials. A total of 78 patientswere treated betweenNovember 2010 andDecember 2012. A Phase II trial ofmonother-
apy HDRB performed for localized prostate cancer using a single implant and two fractions (13.5Gy×2) for a total dose of 27Gy
calculated to be radiobiology of HDRB regimens and BED to 261Gy in 2Gy fractions (˛/ˇ ratio of 1.5Gy). All patients had clinical
Stage T2c or less (AJCC, 5th edition), Gleason score 4–7 (3 + 4), PSA level of ≤15ng/mL. CT scans were done for dosimetry. GU and
GI toxicity were evaluated by CTCAE V 3.0. The highest toxicity scores and self-reported sexual function (patients without BAC)
were recorded during follow-up.
Results. Median follow-up was 9.32 months (range: 2.23–26.07). Grade 1–2 GU acute toxicity was 20.51%, mainly frequency/urgency
(14.1%), dysuria (7.7%), hematuria, dribbling/hesitancy (1.3%). One patient required a Foley catheter during 1 week. No acute GI
toxicities were recorded. The most common early chronic toxicity was Grade 1 urinary frequency/urgency in 1.3% and Grade 2
dysuria in 7.7% of patients; 1 patient had Grade 2 rectal bleeding, 1 had Grade 4, requiring RTU. Twenty-eight patients without
BAC reported potency before therapy; No one of them developed sexual impotence.
Conclusions. A single implant HDR-BT to 27Gy in two fractions within 1 day for localized prostate cancer is feasible with minimal
acute or late toxicity. Longer follow-up is needed to conﬁrm these encouraging early results.
http://dx.doi.org/10.1016/j.rpor.2013.03.707
